期刊文献+

塞来昔布对女性常见恶性肿瘤细胞株的放疗增敏作用 被引量:7

Radiosensitization effect of celecoxib on common malignant tumor cell lines in female patients
下载PDF
导出
摘要 目的观察环氧合酶2(COX-2)选择性抑制剂塞来昔布对人乳腺癌MCF-7细胞株和宫颈癌HeLa细胞株的放射增敏作用。方法用四唑盐比色法(MTT)检测塞来昔布对人乳腺癌MCF-7细胞株和宫颈癌HeLa细胞株的增殖抑制情况;克隆形成实验检测放射增敏作用。结果 MTT检测结果显示塞来昔布对人乳腺癌MCF-7细胞株和宫颈癌HeLa细胞株的增殖有抑制作用,呈现出浓度-时间依赖性;克隆形成实验提示塞来昔布对人乳腺癌MCF-7细胞株和宫颈癌HeLa细胞株有一定程度的放疗增敏效应。结论塞来昔布能增强人乳腺癌MCF-7细胞株和宫颈癌HeLa细胞株的放疗敏感性。 Objective To observe the radiosensitization effect of celecoXib (a selective in- hibitor of cyclooxygenase-2) on human breast cancer MCF-7 cell lines and human cervical cancer HeLa cell lines. Methods The growth inhibition effects of celecoxib on human breast cancer MCF -7 cell lines and human cervical cancer HeLa cell lines were detected by MTT experiment, and the radiosensitization effect of celecoxib was detected by Cloning formation experiment. Results MTT experiment showed the growth inhibition effects of celecoxib on human breast cancer MCF-7 cell lines and human cervical cancer HeLa cell lines were expressed in a concentration and time dependent manner. Cloning formation experiment suggested that celecoxib had a certain degree of radiosensiti- zation effect on human breast cancer MCF-7 cell lines and human cervical cancer HeLa cell lines. Conclusion Celecoxib can enhance the sensitivity of radiotherapy on human breast cancer MCF-7 cell lines and human cervical cancer HeLa cell lines.
出处 《实用临床医药杂志》 CAS 2014年第3期72-75,共4页 Journal of Clinical Medicine in Practice
基金 广东医学院附属医院科研基金项目(QK1111)
关键词 塞来昔布 乳腺肿瘤 宫颈肿瘤 放疗增敏 eelecoxib breast tumor cervical tumor radiosensitization
  • 相关文献

参考文献4

二级参考文献65

  • 1梁世雄,蒋国梁,朱小东,傅小龙,陆海杰,潘朝阳,黄启芳,黎福祥,王安宇.原发性肝癌三维适形放疗后放射性肝病的影响因素[J].中华放射肿瘤学杂志,2005,14(4):284-288. 被引量:42
  • 2王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 3Becker MR, Siegelin MD, Rompel R, et al. COX-2 expression in malignant melanoma: a novel prognostic marker. Melanoma Res, 2009, 19 (1): 8-16.
  • 4Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem, 2007, 43: 59-78.
  • 5De Souza Pereira R. Selective cyclooxygenase-2(COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov, 2009, 4 (2): 157-163.
  • 6Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30 (3): 377-386.
  • 7Lev-Ari S, Lichtenberg D, Arber N. Compositions for treatment of cancer and inflammation. Recent Pat Anticancer Drug Discov, 2008, 3 (1): 55-62.
  • 8Chell S, Kaidi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochem Biophys Acta, 2006, 1766 ( 1 ): 104-119.
  • 9Noda M, Tatsumi Y, Tomizawa M, et al. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherincatenin complexes in gastrointestinal cell lines. J Gastroenterol, 2002, 37 ( 11 ):896-904.
  • 10Toomey DP, Murphy JF, Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon, 2009, 7 ( 3 ): 174-180.

共引文献24

同被引文献67

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部